Infection, Human Immunodeficiency Virus I Clinical Trial
Official title:
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir. This is a 48-week study, where subjects who were assigned to be in their original PI-group have the option of switching to fosamprenavir on week 24. Prior to being assigned their treatment group, subjects had to be suppressed for at least three months. All subjects also take a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03327740 -
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
|
||
| Completed |
NCT00257621 -
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
|
Phase 2 | |
| Completed |
NCT01227824 -
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
|
Phase 3 | |
| Completed |
NCT01597648 -
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
|
Phase 1 | |
| Completed |
NCT01205243 -
ZIAGEN® Post-marketing Surveillance
|
||
| Withdrawn |
NCT01283100 -
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
|
Phase 1 | |
| Completed |
NCT00450580 -
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
|
Phase 3 | |
| Completed |
NCT00440947 -
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
|
Phase 3 | |
| Completed |
NCT00481390 -
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
|
N/A | |
| Completed |
NCT00549198 -
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
|
Phase 4 | |
| Completed |
NCT00242840 -
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
|
Phase 3 | |
| Terminated |
NCT00197145 -
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
|
Phase 3 | |
| Completed |
NCT00089583 -
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
|
Phase 2 | |
| Completed |
NCT00044577 -
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
|
Phase 3 | |
| Terminated |
NCT00104429 -
GW873140 In Combination With Combivir In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT01263015 -
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
|
Phase 3 | |
| Terminated |
NCT00102778 -
GW873140 In Combination With Kaletra In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT00046176 -
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
|
Phase 3 | |
| Terminated |
NCT00242879 -
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
|
Phase 2 | |
| Completed |
NCT00082394 -
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
|
Phase 4 |